The Possible Effects of Dapagliflozin on 12-derived Electrocardiogram in Patients with Type 2 Diabetes Mellitus

Basit Öğe Kaydı
dc.contributor.authorAkkus, Oguz
dc.contributor.authorAkkus, Gamze
dc.contributor.authorKaypakli, Onur
dc.date.accessioned2024-09-18T21:00:27Z
dc.date.available2024-09-18T21:00:27Z
dc.date.issued2019
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground: Dapagliflozin, sodium glucose cotransporter 2 inhibitor, has potential side effects on electrolyte imbalance as it has diuretic effects which include decreasing glucose reabsorption, increasing glucosuria and natriuresis. We aimed to determine the possible effects of dapagliflozin on electrocardiogram (ECG) in patients with type 2 DM. Material and Methods: This retrospective study consisted of 49 patients (25 female, 24 male). Patients who had inadequate glycemic control besides using several oral antidiabetics, subsequently endorsed with dapagliflozin, were included in the current study. Results: Meantime interval from treatment initiation to control was 10.5 +/- 5.03 weeks. Body mass index, glucose, HbAlC, eGFR, LDL-C, heart rate, systolic and diastolic blood pressures were found to be significantly lower at control admission (p<0.05). Creatinine and QT interval were significantly higher at control admission (p<0.05). Baseline Tpe duration and baseline Tpe/QT ratio were found to be significantly correlated with Tpe/QT difference (p<0.05). In linear regression analysis, baseline Tpe/QT ratio was found to be the sole independent predictor of Tpe/QT difference (p<0.05). Conclusion: Initiation of dapagliflozin treatment seems to be safe, up to several months, in terms of serum electrolytes and ECG findings in patients with type 2 DM with a probable improvement.en_US
dc.identifier.doi10.2174/1871530319666181218121508
dc.identifier.endpage213en_US
dc.identifier.issn1871-5303
dc.identifier.issn2212-3873
dc.identifier.issue2en_US
dc.identifier.pmid30569879en_US
dc.identifier.scopus2-s2.0-85061858751en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage207en_US
dc.identifier.urihttps://doi.org/10.2174/1871530319666181218121508
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12693
dc.identifier.volume19en_US
dc.identifier.wosWOS:000458025000014en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofEndocrine Metabolic & Immune Disorders-Drug Targetsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectType 2 diabetes mellitusen_US
dc.subjectSGLT 2 inhibitoren_US
dc.subjectelectrolyte imbalanceen_US
dc.subject12-derived electrocardiogramen_US
dc.subjectTpe/QTen_US
dc.subjectcardiovascular responseen_US
dc.titleThe Possible Effects of Dapagliflozin on 12-derived Electrocardiogram in Patients with Type 2 Diabetes Mellitusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu